Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
AssigneePfizer Inc.
InventorsRobin Lee Keich, David Ross McGavin, Robert J. Yancey
Life of this patent
Estimating the term…
Abstract
The present invention relates to Mycoplasma bovis vaccines and methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma bovis by administering to the animal an effective amount of a Mycoplasma bovis vaccine. The Mycoplasma bovis vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The Mycoplasma bovis vaccine administered in accordance with the present can be synthesized or recombinantly produced. The invention also relates to combination vaccines, methods of preparing Mycoplasma bovis vaccines and kits.
Claims55
A vaccine formulation for immunization of an animal comprising an immunologically effective amount of an inactivated, whole or partial Mycoplasma bovis cell and a pharmaceutically acceptable carrier.
A method of treating or preventing a disease or disorder in an animal caused by infection with Mycoplasma bovis, comprising administering to the animal, an effective amount of a Mycoplasma bovis vaccine.
A method of preparing a Mycoplasma bovis vaccine comprising growing a isolate of Mycoplasma bovis in culture in a suitable medium;
- treating the Mycoplasma bovis with binary etheleneimine to inactivate the Mycoplasma bovis;
- and admixing the inactivated Mycoplasma bovis with a suitable pharmaceutically acceptable carrier.
A kit comprising in at least one container a Mycoplasma bovis bacterin and an adjuvant.
A bacterin comprising an inactivated Mycoplasma bovis isolate in an amount of about 5×108 colony forming units per dose of bacterin, in a pharmaceutically acceptable carrier.
A vaccine formulation for immunization of an animal comprising an immunologically effective amount of an inactivated, whole or partial Mycoplasma bovis cell and an adjuvant comprising Quil A, cholesterol and Amphigen.
A method of treating or preventing a disease or disorder in an animal caused by infection with Mycoplasma bovis and at least one other heterologous strain, comprising administering to the animal, an effective amount of a Mycoplasma bovis vaccine.
A vaccine formulation for immunization of an animal comprising an immunologically effective amount of an inactivated, whole or partial Mycoplasma bovis cell and OneShot™ (M.haemolytica), or Bovishield™ (BRSV/BVD-1/BVD-2/BHV-1/PI3, or H. somunus or P. Multocida, or any combination thereof.
A vaccine formulation for immunization of an animal comprising an immunologically effective amount of an inactivated, whole or partial Mycoplasma bovis cell, wherein the Mycoplasma bovis is the strain designated as ATCC PTA-3685.
Dependencies are inferred from the claim text.